title: N-cadherin antagonists as oncology therapeutics.
abstract: The cell adhesion molecule (CAM), N-cadherin, has emerged as an important oncology therapeutic target. N-cadherin is a transmembrane glycoprotein mediating the formation and structural integrity of blood vessels. Its expression has also been documented in numerous types of poorly differentiated tumours. This CAM is involved in regulating the proliferation, survival, invasiveness and metastasis of cancer cells. Disruption of N-cadherin homophilic intercellular interactions using peptide or small molecule antagonists is a promising novel strategy for anti-cancer therapies. This review discusses: the discovery of N-cadherin, the mechanism by which N-cadherin promotes cell adhesion, the role of N-cadherin in blood vessel formation and maintenance, participation of N-cadherin in cancer progression, the different types of N-cadherin antagonists and the use of N-cadherin antagonists as anti-cancer drugs.
authors.affiliation: Division of Urology, Department of Surgery, McGill University, Montreal, Quebec, Canada H3A 1A1 orest.blaschuk@mcgill.ca.
authors.forename: Orest W
authors.initials: OW
authors.lastname: Blaschuk
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D015820:Cadherins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D002448:Cell Adhesion / Q000187:drug effects / Q000502:physiology; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D009369:Neoplasms / Q000235:genetics / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D015820:Cadherins
keywords: ADH-1; N-cadherin antagonists; angiogenesis; cancer; endothelial cells